Gensight Biologics S.a annual net debt
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Net Debt Growth & History (SIGHT)
Gensight Biologics S.a's net debt was €10.4M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €10.4M | €5.5M | +109.97% |
| 2024 | 2024-12-31 | €5.0M | −€2.2M | −30.53% |
| 2023 | 2023-12-31 | €7.2M | €14.7M | — |
| 2022 | 2022-12-31 | −€7.5M | €34.5M | — |
| 2021 | 2021-12-31 | −€42.0M | −€6.7M | — |
| 2020 | 2020-12-31 | −€35.3M | — | — |
Gensight Biologics S.a quarterly net debt
Q4.24
Q4.25
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | €10.4M | −€1.5M | −12.56% |
| Q4 2024 | 2024-12-31 | €11.9M | — | — |
Gensight Biologics S.a net debt trends
Over the last five fiscal years, Gensight Biologics S.a's net debt increased from −€35.3M to €10.4M, a change of €45.8M. The latest reported quarter, Q4 2025, shows €10.4M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...